QIANHAI HEALTH HOLDINGS LIMITED 前海健康控股有限公司 (the "Company" and "本公司") Terms of reference of the Nomination Committee (the "Committee") of the Board (the "Board") of Directors (the "Directors") of the Company 董事("董事")會("董事會") 提名委員會("委員會") 權責範圍及程序 (中文本爲翻譯稿，僅供參考用) QIANHAI HEALTH HOLDINGS LIMITED 前海健康控股有限公司 董事會提名委員會職權範圍 Terms of reference of the Nomination Committee of the Board of Directors 1. Constitution 組成 1.1 The Committee is established pursuant to a resolution passed by the Board at its meeting held on 9 ...

Qianhai Health Holdings Limited 前海健康控股有限公司 ( 於開曼群島註冊成立的有限公司） （股份代號：911） 董事名單以及角色及職能 黃志群先生 (董事會主席) 陳凱犇先生 陳琦先生 湯裕源先生 源自立先生 獨立非執行董事 李煒先生 梁振東先生 吳鴻茹女士 董事會設立三個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 | | 董事委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | --- | | 董事 | | | | | | 黃志群先生 | | - | - | - | | 陳凱犇先生 | | - | - | - | | 陳琦先生 | | - | - | - | | 湯裕源先生 | | - | - | - | | 源自立先生 | | - | 成員 | 成員 | | 李煒先生 | | 成員 | 主席 | 主席 | | 梁振東先生 | | 成員 | 成員 | 成員 | | 吳鴻茹女士 | | 主席 | - | 成員 | 香港，二零二五年六月二十五日 前海健康控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內容而 引致的任何損失承擔任何責任。 香港，二零二五年六月二十五日 於本公告日期，非執行董事為黃志群先生、陳凱犇先生及陳琦先生；執行董事為湯裕源先生及 源自立先生及獨立非執行董事為李煒先生、梁振東先生及吳鴻茹女士。 1 前海健康控股有限公司（「本公司」）董事會（「董事會」）欣然宣布，本公司之獨立非執行 董事吳鴻茹女士已獲委任為本公司之提名委員會（「提名委員會」）之成員，自二零二五年六 月二十五日起生效。 於上述委任後，提名委員會由李煒先生（提名委員會主席）、源自立先生、梁振東先生及吳鴻 茹女士組成。 董事會謹藉此衷心歡迎吳鴻茹女士加入提名委員會。 承董事會命 前海健康控股有限公司 主席 黃志群 Qianhai Health Holdings Limited 前海健康控股有限公司 （於開曼群島註冊成立的有限公司） (股份代號: 911) 委任提名委員會成員 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本通告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 前海健康控股有限公 司 Qianhai Health Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：911） 股東週年大會通告 茲通告前海健康控股有限公司（「本公司」）謹訂於二零二五年六月二十五日（星期三） 上午十一時三十分假座香港上環文咸東街35-45B號2樓室舉行股東週年大會，藉以 處理下列事項： 前海健康控股有限公司 主席 除非另有說明，否則本通告中所用詞彙與本公司日期為二零二五年五月二十七日致 股東之通函（「通函」）所界定者具有相同涵義。 普通決議案 1 1. 省覽及批准本公司及其附屬公司截至二零二四年十二月三十一日止年度之經 審核綜合財務報表以及董事會報告及本公司之核數師報告； 2. 考慮及酌情批准下列各項決議案（各自作為獨立之決議案）： (a) 重選湯裕源先生為董事； (b) 重選源自立先生為董事； (c) 重選陳凱犇先生為董事； (d) 重選吳鴻茹女士為董事 ...

此乃要件 請即處理 閣下如對本通函任何方面有疑問，應諮詢 閣下之股票經紀或其他註冊證券商、銀行經理、 律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓名下之所有前海健康控股有限公司股份，應立即將本通函及隨附之代 表委任表格交予買主或承讓人，或送交經手買賣或轉讓之銀行、股票經紀或其他代理商，以 便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 本通函所用詞彙應與本通函「釋義」一節所界定者具相同涵義。 前海健康控股有限公 司 Qianhai Health Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：911） 重選退任董事 及 股東週年大會通告 前海健康控股有限公司謹訂於二零二五年六月二十五日（星期三）上午十一時三十分假座香 港上環文咸東街35-45B號2樓舉行股東週年大會，召開大會之通告載於本通函第10至12頁。 隨函亦附奉股東週年大會適用之代表委任表格。無論 閣下能否出席該大會，謹請按照代表 委 ...

Financial Performance - The company reported revenue of approximately HKD 519.7 million for the fiscal year 2024, a decrease from HKD 961.3 million in 2023, primarily due to a decline in sales volume [6]. - The gross profit for the year was HKD 29.7 million, compared to a gross loss of HKD 35.6 million in the previous year, resulting in a gross margin of 5.7% [9]. - The company achieved a profit attributable to owners of approximately HKD 1.3 million, a significant turnaround from a loss of HKD 52.7 million in the prior year [12]. - Total assets decreased to HKD 407.3 million from HKD 478.1 million, while total liabilities significantly reduced to HKD 21.7 million from HKD 94.0 million [6]. - The company anticipates continued volatility in ICs and NAND flash wafer prices, impacting future revenue stability [8]. - Other losses included an additional provision of approximately HKD 60.4 million for loss contracts due to unexpected costs exceeding anticipated economic benefits [11]. - The company maintained a net asset value of HKD 385.6 million, slightly up from HKD 384.1 million in the previous year [6]. - The group anticipates growth opportunities in the electronic components industry driven by advanced technologies such as third-generation semiconductor materials, 5G, AI, and automotive electronics [13]. Asset and Liability Management - As of December 31, 2024, the current ratio is approximately 18.1 times, significantly up from 4.8 times in 2023 [14]. - Total assets as of December 31, 2024, are approximately HKD 407.3 million, down from HKD 478.1 million in 2023 [14]. - The group’s capital debt ratio is approximately 5.3% as of December 31, 2024, compared to 19.7% in 2023 [14]. - Inventory held as of December 31, 2024, is approximately HKD 188.8 million, a decrease from HKD 329.8 million in 2023 [15]. - Prepayments for inventory purchases amount to approximately HKD 70.6 million as of December 31, 2024, down from HKD 102.0 million in 2023 [16]. - Trade receivables as of December 31, 2024, are approximately HKD 98.7 million, with an expected credit loss provision of about HKD 0.3 million [18]. - Cash and cash equivalents are approximately HKD 23.3 million as of December 31, 2024, an increase from HKD 19.5 million in 2023 [19]. - The group has no borrowings as of December 31, 2024 [20]. Corporate Governance - The company has established a robust internal control system to ensure compliance and accountability, adhering to the corporate governance code as per the listing rules [40]. - The board consists of eight members, including three non-executive directors, two executive directors, and three independent non-executive directors, ensuring a balanced power structure [43]. - The company emphasizes a diverse board composition, considering various factors such as gender, age, ethnicity, and professional experience, to enhance governance effectiveness [48]. - The company has implemented an anti-corruption policy and reporting mechanism to promote ethical behavior and compliance among employees [41]. - The board has mechanisms in place to ensure independent viewpoints are considered, including encouraging active participation from independent non-executive directors [47]. - The company is currently seeking a suitable candidate for the CEO position, which has been vacant since July 18, 2019 [46]. - The company has adopted a code of conduct for securities trading by directors, ensuring compliance with the standards set forth in the listing rules [42]. - The board conducts annual reviews of its diversity policy and its effectiveness in achieving measurable goals [48]. Employee Relations and Compensation - The total salary and related costs for the 16 employees as of December 31, 2024, amount to approximately HKD 6.6 million [30]. - The company has established an annual review system to assess employee performance, which forms the basis for salary increases, bonuses, and promotions [30]. - The board believes in maintaining a good relationship with employees [30]. - The company has adopted a share option scheme to reward directors and eligible employees based on individual performance [30]. - The company has maintained a zero-tolerance policy towards any form of discrimination and has not reported any incidents of workplace discrimination or harassment this year [190]. - The company offers competitive and fair compensation and benefits to attract high-quality talent, with regular salary reviews to recognize employee contributions [190]. Risk Management - The company has established a risk management and internal control system to minimize procurement price risks and protect assets [80]. - The board believes the risk management and internal control systems are adequate and effective as of December 31, 2024 [82]. - The main risks faced by the company include credit risk, currency risk, and liquidity risk [160]. Environmental, Social, and Governance (ESG) Initiatives - The company is committed to environmental responsibility by managing its operational impact and improving resource efficiency [153]. - The company has established an Environmental, Social, and Governance (ESG) working group to assess and manage ESG-related risks [166]. - The ESG report emphasizes the importance of stakeholder engagement and has conducted a materiality assessment to identify key concerns [167][171]. - The company has implemented an environmental strategy focused on "saving, reusing, and recycling" to enhance energy efficiency and reduce carbon emissions [179]. - The company has established a collection area for recyclable materials, including paper, plastic, and metal, to support waste recycling efforts [175]. - The company is committed to complying with all relevant environmental laws and regulations applicable to its operations [172]. - The company has not recorded any significant non-compliance issues with applicable environmental protection laws and regulations as of December 31, 2024 [186]. Shareholder Relations - The board is committed to effective communication with shareholders to enhance investor relations and ensure timely disclosure of information [88]. - Shareholders holding at least 10% of the paid-up capital can request the board to convene a special general meeting [89]. - The company has updated its articles of association to comply with the latest regulatory requirements regarding paperless listing systems [93]. - The company reported total distributable reserves of approximately HKD 262,991,000 as of December 31, 2024, compared to HKD 233,372,000 in 2023, reflecting an increase of about 12.5% [107]. Compliance and Legal Matters - The company has adhered to relevant laws and regulations that significantly impact its business operations [151]. - The company has implemented appropriate internal controls and quality control measures to ensure compliance with the Sale of Goods Ordinance [156]. - The group complies with all applicable laws and regulations related to product responsibility, with no known violations during the year [199]. - The group has adopted high-standard security and confidentiality measures to protect stakeholders' personal data [200].

Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of HKD 519,699,000, a decrease of 46% compared to HKD 961,291,000 in the previous year[2] - The cost of sales for the same period was HKD 490,029,000, resulting in a gross profit of HKD 29,670,000, compared to a gross loss of HKD 35,603,000 in the previous year[2] - The net profit attributable to the company's owners for the year was HKD 1,311,000, a significant recovery from a net loss of HKD 52,705,000 in the previous year[2] - The basic and diluted earnings per share improved to HKD 0.77 from a loss of HKD 31.10 in the previous year[2] - The company reported other income of HKD 243,000 for the year ended December 31, 2024, compared to HKD 69,000 in 2023, indicating a significant increase[32] - The net other losses for the year ended December 31, 2024, amounted to HKD 12,828,000, compared to HKD 548,000 in 2023, reflecting a substantial increase in losses[33] - The financing costs for the year ended December 31, 2024, were HKD 23,000, down from HKD 43,000 in 2023, showing a decrease in financing expenses[34] - The company reported a profit attributable to owners of HKD 1,311,000 in 2024, a significant recovery from a loss of HKD 52,705,000 in 2023[39] - The gross profit for the year was approximately HKD 29.7 million, a turnaround from a gross loss of HKD 35.8 million in 2023, resulting in a gross margin of 5.7% compared to a gross loss margin of 3.7% in the previous year[54][56] Assets and Liabilities - The company's total assets decreased to HKD 407,309,000 from HKD 478,117,000, reflecting a decline of approximately 15%[5] - Current assets were reported at HKD 386,155,000, down from HKD 451,652,000, indicating a reduction of about 14%[5] - The company's total equity increased slightly to HKD 385,570,000 from HKD 384,114,000, showing a marginal growth of 0.4%[5] - Trade receivables, net of impairment, amounted to HKD 98,746,000 in 2024, compared to zero in 2023, indicating an increase in credit sales[44] - As of December 31, 2024, the current ratio was approximately 18.1 times, up from 4.8 times in 2023[59] - Total assets as of December 31, 2024, were approximately HKD 407.3 million, down from HKD 478.1 million in 2023[59] - The company's capital debt ratio was approximately 5.3% as of December 31, 2024, compared to 19.7% in 2023[59] - Inventory held as of December 31, 2024, was approximately HKD 188.7 million, down from HKD 329.8 million in 2023[62] - Trade receivables amounted to approximately HKD 98.7 million as of December 31, 2024, with an expected credit loss provision of approximately HKD 0.3 million[65] - Cash and cash equivalents were approximately HKD 23.3 million as of December 31, 2024, compared to HKD 19.5 million in 2023[66] - The company had no borrowings as of December 31, 2024[67] Business Operations - The company is primarily engaged in the sale of health products and electronic components, with a focus on expanding its market presence[9] - The company has focused solely on the electronic components business in 2024, with no sales from health products and food[52] - The company completed the sale of its entire interest in Hong Wang Holdings Limited on November 28, 2024[70] - The company has adopted a diversified strategy to optimize product structure and supply chain, aiming for stable business operations amid industry fluctuations[54] - The company is actively developing its healthcare business and exploring opportunities for collaboration with industry peers, focusing on various health products and foods[81] - The company aims to maintain a diversified product category and customer base strategy to uncover new business opportunities[81] - The company will monitor market changes and adjust strategies as needed to enhance profitability and resilience against risks, while striving to deliver substantial returns to investors[81] Future Outlook - The company has not yet applied any new accounting standards that are effective for the fiscal year starting January 1, 2024, which may impact future financial reporting[16] - The company is currently assessing the impact of the new Hong Kong Financial Reporting Standards on its consolidated financial statements, which may lead to significant changes in presentation and disclosure[20] - The company anticipates that the demand for ICs and NAND flash wafers will fluctuate in the second half of 2024, impacting overall pricing trends[53] - Strong demand in the smartphone and server markets is anticipated to significantly boost memory demand, with AI-enabled smart devices likely accelerating replacement cycles in the mid to long term[81] - The gradual development of advanced technologies such as third-generation semiconductor materials, 5G, AI, and automotive electronics is expected to create new growth opportunities in the electronic components industry[81] Dividends and Shareholder Returns - The company did not recommend any dividends for the years ended December 31, 2024, and 2023[43] - The board does not recommend the payment of a final dividend for the year[75] - The basic earnings per share for the year ended December 31, 2024, will be calculated based on the profit attributable to the owners of the company and the weighted average number of ordinary shares issued[38] - The company adopted a stock option plan effective from June 27, 2024, which is valid for ten years, but no stock options have been granted under this plan to date, resulting in a zero impact on the weighted average number of shares issued this year[77] Segment Reporting - The company has identified its reportable segments based on the internal reports reviewed by the executive directors, focusing on different product lines[22] - The company has no inter-segment sales for the years ended December 31, 2024, and 2023, indicating that all revenue is generated from external customers in Hong Kong[30] - The company has not presented segment assets and liabilities as these amounts are not regularly reviewed by the chief operating decision maker for resource allocation and performance assessment[29]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 前海健康控股有限公司 主席 黃志群先生 香港，二零二五年三月十日 於本公告日期，非執行董事為黃志群先生、陳凱犇先生及陳琦先生；執行董事為 湯裕源及源自立先生; 及獨立非執行董事為李煒先生、梁振東先生及吳鴻茹女 士。 Qianhai Health Holdings Limited 前海健康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：911） 董事會會議召開日期 前海健康控股有限公司（「本公司」）董事（「董事」）組成之董事會（「董事會」） 謹此宣佈，本公司董事會會議將於二零二五年三月二十四日（星期一）舉行，以 （其中包括）批准本公司及其附屬公司截至二零二四年十二月三十一日止之經審 核財政年度業績及其刊發，並及考慮派發末期股息之建議（如有）。 承董事會命 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 前海健康控股有限公 司 Qianhai Health Holdings Limited （於開曼群島註冊成立的有限公司） （股份代號：911） 正面盈利預告 本公告由前海健康控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）根據香港聯合交易所有限公司證券上市規則（「上市規則」） 第13.09條及香港法例第571章證券及期貨條例第XIVA部項下之內幕消息條文（定義 見上市規則）作出。 董事會謹此通知本公司股東（「股東」）及潛在投資者，根據本集團截至二零二四年 十二月三十一日止年度（「本年度」）之未經審核管理帳目（「管理帳目」）之初步審閱 及董事會目前可得資料，本集團預期錄得股東應佔溢利約1,300,000港元（「預期溢 利」），跟截至二零二三年十二月三十一日止年度（「上年度」）錄得約52,700,000港元之 虧損相比，實現轉虧為盈。 本年度轉虧為盈主要是由於以下各 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分 內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qianhai Health Holdings Limited 前海健康控股有限公司 （於開曼群島註冊成立的有限公司） (股份代號: 911) 補充公告 有關出售事項之須予披露交易 出售事項完成後，出售事項將導致目標公司的資產和負債(主要包括重大資產和 負債) 不再合併於本公司之合併財務報表中。該解除合併將導致集團一次性出售 事項收益約為 5180 萬港元（待公司審計師進行最終審計）。 出售事項所得款項之預期用途 出售事項所得款項將用於集團的一般營運資金。 承董事會命 前海健康控股有限公司 主席 黃志群 香港，二零二四年十二月二十日 謹此提述前海健康控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 於二零二四年十二月六日就有關出售事項之須予披露交易之公告（「該公告」）。 除另有指明外，本公告所用詞彙與該公告所界定者具有相同涵義。 本公司欲進一步公開更多有關出售事項之詳細情況。 志成之附加資訊 ...